HIPAA Alert: Potential Data Breach Learn More

Close this search box.

Mount Holly oncologist Seth Howard Berk discusses Melanoma trends in Burlington County, Treatment Advances

Dr. Seth Howard Berk, a board-certified hematologist and medical oncologist who practices in Mount Holly, NJ with Regional Cancer Care Associates (RCCA), discusses new developments in oncology treatments for skin disorders. Dr. Berk mentions that many of the new tools used in combating skin cancers focus on harnessing the power of the immune system, and that these new developments have already begun saving the lives of cancer patients.

According to the National Cancer Institute (NCI), an estimated 76,380 people are diagnosed with Melanoma each year. Of that number, Melanoma will claim the lives of 10,130 people. Dr. Berk goes on to state that, on average, 137 people in Burlington County, New Jersey are diagnosed with Melanoma each year, and of that, an average of 15 county residents will die as a result of the cancer.

Dr. Berk advises that some common-sense precautions be taken to prevent sun damage to skin, including avoiding prolonged exposure to the sun, and wearing effective sunscreen. Having moles or other suspicious skin markings evaluated by doctors is also integral in the timely diagnosis and treatment of any developing skin issues, says Dr. Berk. At RCCA, Dr. Berk uses a full range of available cancer treatment options, including immunotherapy, for patients with Melanoma and other skin ailments.

To read more, check out “Mount Holly oncologist Seth Howard Berk discusses Melanoma trends in Burlington County, treatment advances.”

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.


Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.